Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker RBGLY · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Dec 30, 2020 | Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute… NCT01202279 · Acute Upper Respiratory Track Infection Guaifenesin, Placebo | RBGLY Reckitt Benckiser Inc. | Phase 4 | Completed | 1,179 | Apr 2010 | Registry ↗ |
| Dec 30, 2020 | Mucinex Exploratory Cold Study NCT01046136 · Common Cold guaifenesin (Mucinex), placebo | RBGLY Reckitt Benckiser Inc. | Phase 2 | Completed | 378 | Mar 2010 | Registry ↗ |
| Jun 20, 2019 | Study to Evaluate Drug-drug Interactions of Guaifenesin and Hydrocodone Bitartrate NCT03642873 · Healthy Subjects Humibid®, Hydrocodone Bitartrate | RBGLY Reckitt Benckiser LLC | Phase 1 | Completed | 24 | May 21, 2007 | Registry ↗ |
| Jun 19, 2019 | Bioequivalence Study Comparing Mucinex Extended-release 600 mg Tablets to Immediate-release Guaifen… NCT03644095 · Healthy Subjects Mucinex® SE, Vicks Cough Syrup for Chesty Coughs | RBGLY Reckitt Benckiser Inc. | Phase 1 | Completed | 30 | Feb 1, 2009 | Registry ↗ |
| Jun 17, 2019 | Mucinex® ER 600 mg Bi-layer Tablet Versus Guaifenesin Immediate Release (IR) 200 mg q4h NCT03642262 · Healthy Subjects Mucinex® | RBGLY Reckitt Benckiser Inc. | Phase 1 | Completed | 30 | Aug 9, 2013 | Registry ↗ |
| Jun 17, 2019 | Study to Evaluate the Pharmacokinetics of Guaifenesin in Adults and Adolescents NCT03633448 · Healthy Subjects Children's Mucinex® Grape Flavor, Children's Mucinex® Grape… | RBGLY Reckitt Benckiser LLC | Phase 1 | Completed | 24 | Jul 1, 2011 | Registry ↗ |
| Mar 27, 2019 | Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted NCT03649750 · Healthy Subjects Mucinex® | RBGLY Reckitt Benckiser LLC | Phase 1 | Completed | 36 | Aug 7, 2013 | Registry ↗ |
| Mar 27, 2019 | Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in… NCT03643575 · Healthy Subjects Vicks Cough Syrup for Chesty Coughs, Robitussin Extra Stren… | RBGLY Reckitt Benckiser Inc. | Phase 1 | Completed | 30 | Jul 16, 2009 | Registry ↗ |
| Mar 19, 2019 | Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-L… NCT03725085 · Healthy Subjects Mucinex™ extended-release (SE) | RBGLY Reckitt Benckiser LLC | Phase 4 | Completed | 552 | Oct 16, 2015 | Registry ↗ |
| Feb 28, 2019 | Study to Evaluate the Pharmacokinetics of Mucinex 600 mg Extended-release Bi-layer Tablet in Health… NCT03644108 · Healthy Subjects Mucinex® ER 600 mg | RBGLY Reckitt Benckiser Inc. | Phase 1 | Completed | 30 | Jun 15, 2009 | Registry ↗ |
| Feb 28, 2019 | Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Tablet NCT03633487 · Healthy Subjects Mucinex® | RBGLY Reckitt Benckiser LLC | Phase 1 | Completed | 24 | Oct 15, 2011 | Registry ↗ |
| Sep 19, 2018 | Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respirat… NCT01114581 · Acute Respiratory Infection Mucinex, Placebo | RBGLY Reckitt Benckiser LLC | Phase 2 | Completed | 38 | Apr 2011 | Registry ↗ |
| Sep 17, 2018 | Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study NCT01229449 · Post-operative Pain Ibuprofen/acetaminophen, Ibuprofen/acetaminophen (higher do… | RBGLY Reckitt Benckiser LLC | Phase 3 | Completed | 678 | Sep 2009 | Registry ↗ |
| Oct 11, 2017 | Safety & Performance Study of Verruca Treatment Device NCT01536834 · Verruca, Plantar Wart Medical Device | RBGLY Reckitt Benckiser LLC | Not applicable | Completed | 35 | Jan 2013 | Registry ↗ |
| Sep 28, 2017 | Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method NCT01986361 · Acute Pharyngitis, Sore Throat flurbiprofen, placebo | RBGLY Reckitt Benckiser LLC | Phase 3 | Completed | 122 | Apr 2014 | Registry ↗ |
| Sep 21, 2017 | A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis NCT01049334 · Pharyngitis Placebo, Flurbiprofen | RBGLY Reckitt Benckiser LLC | Phase 3 | Completed | 204 | Mar 2011 | Registry ↗ |
| Sep 21, 2017 | A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis NCT01048866 · Pharyngitis placebo, flurbiprofen | RBGLY Reckitt Benckiser LLC | Phase 3 | Completed | 198 | Mar 2011 | Registry ↗ |
| Sep 11, 2017 | Evaluation of Tolerance and Acceptability of a Coated Condom NCT01619397 · Tolerance and Acceptability of a New Condom Coating Test condom with new Xanthan gum condom coating | RBGLY Reckitt Benckiser LLC | Not applicable | Completed | 50 | Oct 2012 | Registry ↗ |
18 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:52 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances